Smoldering vs. Active Multiple Myeloma: The SLiM-CRAB Biomarkers That Trigger Treatment Before Organ Damage

Multiple myeloma is a blood cancer involving abnormal plasma cells, a type of white blood cell that normally makes antibodies. These cancerous cells usually grow in the bone marrow and can produce an abnormal antibody called a monoclonal protein, or “M protein.”

Not everyone with abnormal plasma cells has active multiple myeloma. Some people have an earlier condition called smoldering multiple myeloma, which may not cause symptoms or organ damage. The key question is whether testing shows a high enough risk that treatment should begin—even before traditional complications appear.

Doctors use the SLiM-CRAB criteria, based on recommendations from expert groups such as the International Myeloma Working Group (IMWG), to distinguish active multiple myeloma from smoldering disease.

What is smoldering multiple myeloma?

Smoldering multiple myeloma is an intermediate condition between monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma.

In smoldering disease:

• Abnormal plasma cells are present in the bone marrow.
• The M protein or abnormal light chains are higher than would be expected with MGUS.
• There may be no symptoms.
• There is no evidence of myeloma-related organ damage.
• The person does not yet meet the biomarker criteria that predict a very high likelihood of developing organ damage soon.

Smoldering multiple myeloma is not simply “nothing to worry about.” It can progress to active multiple myeloma, but the risk varies greatly from person to person. Some people remain stable for years, while others progress more quickly.

For this reason, monitoring is individualized. Follow-up commonly includes blood and urine tests, imaging, and sometimes repeat bone marrow evaluation.

What is active multiple myeloma?

Active multiple myeloma means that the abnormal plasma cells are causing significant disease. This can be shown by classic organ damage, known as CRAB features, or by certain highly predictive biomarkers, known as SLiM criteria.

A diagnosis usually requires:

1. At least 10% clonal plasma cells in the bone marrow or a biopsy-proven plasmacytoma, and
2. At least one myeloma-defining event—either a CRAB feature or a SLiM biomarker.

The word “active” does not always mean a person feels ill. Some people have active multiple myeloma based on laboratory or imaging results before they notice symptoms. That is why regular follow-up is important.

The CRAB criteria: evidence of organ damage

CRAB refers to:

• C — Calcium elevation
• R — Renal, or kidney, impairment
• A — Anemia
• B — Bone lesions

These findings must generally be judged to be caused by the plasma cell disorder rather than by another medical condition.

C: High calcium

Multiple myeloma can cause calcium to leave weakened bones and enter the bloodstream. Clinically significant hypercalcemia is generally defined as:

• A calcium level more than 1 mg/dL above the upper limit of normal, or
• A calcium level above approximately 11 mg/dL

High calcium may cause thirst, frequent urination, constipation, nausea, weakness, confusion, or dehydration. Mild abnormalities can have other causes, so doctors may repeat the test and consider albumin levels or measure ionized calcium.

R: Kidney impairment

Abnormal light chains produced by myeloma can damage the kidneys. A myeloma-related kidney problem may be reflected by:

• Creatinine above 2 mg/dL, or
• Estimated creatinine clearance below 40 mL per minute

Kidney function can also be affected by dehydration, medications, infection, diabetes, or other conditions. Doctors therefore assess the overall pattern, including urine protein, free light chains, hydration, and medication use.

New or worsening kidney problems require prompt medical attention. Severe dehydration, very low urine output, confusion, or sudden weakness should be treated as urgent concerns.

A: Anemia

Myeloma cells can crowd the bone marrow and reduce the production of healthy red blood cells. Anemia meeting the CRAB definition is generally:

• Hemoglobin below 10 g/dL, or
• More than 2 g/dL below the lower limit of normal

Anemia may cause tiredness, shortness of breath with activity, dizziness, headaches, or a fast heartbeat. However, anemia is common and may result from iron deficiency, bleeding, kidney disease, vitamin deficiencies, or chronic inflammation. The cause needs to be established before linking it to multiple myeloma.

B: Bone lesions

Multiple myeloma can create areas of bone destruction, often called lytic lesions. One or more clearly defined osteolytic lesions on imaging can meet the bone criterion.

X-rays may miss early or small lesions. Depending on the situation, doctors may use low-dose whole-body CT, PET-CT, or MRI. Bone pain—especially persistent back, rib, hip, or skull pain—should not automatically be assumed to be cancer, but it deserves medical evaluation when it continues or worsens.

The SLiM biomarkers: treatment before organ damage

The SLiM criteria were added because some test results predict a very high chance of developing CRAB-related damage in the near future. In these situations, waiting for kidney failure, severe anemia, high calcium, or fractures could allow avoidable harm.

S: Sixty percent or more plasma cells in bone marrow

If testing shows 60% or more clonal plasma cells in the bone marrow, this is considered a myeloma-defining event.

This percentage is determined through bone marrow aspiration and biopsy. The result can be affected by how the sample is collected and whether the disease is evenly distributed, so specialists interpret it alongside other findings.

Li: Light-chain ratio of 100 or higher

The involved-to-uninvolved serum free light-chain ratio may qualify as a myeloma-defining biomarker when:

• The ratio is at least 100, and
• The involved free light-chain level is at least 100 mg/L

Plasma cells may produce excessive kappa or lambda light chains. A very abnormal ratio, particularly at this level, indicates a high burden of abnormal plasma cell activity.

Kidney disease and other conditions can influence free light-chain results. The numbers must be interpreted by a clinician familiar with the test and the patient’s kidney function.

M: More than one focal lesion on MRI

MRI may show areas of concentrated abnormal plasma cells in the bone marrow, called focal lesions. More than one focal lesion, with each measuring at least 5 mm, is a myeloma-defining event.

MRI findings are interpreted alongside the clinical history and other scans. A suspicious area is not always cancer, and radiologists may recommend additional imaging or follow-up when the result is uncertain.

Why SLiM-CRAB changes treatment decisions

Historically, doctors often waited to treat multiple myeloma until organ damage appeared. Current evidence shows that certain SLiM biomarkers are associated with a very high risk of developing damage within a relatively short period. These findings can justify starting treatment earlier.

Treatment decisions may include:

• Combination drug therapy to reduce the abnormal plasma cell population
• Consideration of an autologous stem cell transplant for eligible patients
• Maintenance treatment after initial therapy
• Supportive care for bones, kidneys, infections, anemia, or other complications

By contrast, many people with smoldering multiple myeloma are monitored rather than treated immediately. Selected people at particularly high risk may discuss early treatment or a clinical trial with a hematologist-oncologist. Treatment is not automatically appropriate for every person with smoldering disease.

What testing is usually involved?

Evaluation may include:

• Complete blood count
• Calcium and kidney-function tests
• Serum protein electrophoresis and immunofixation
• Quantitative immunoglobulins
• Serum free light-chain testing
• Urine protein studies
• Bone marrow biopsy
• Whole-body CT, PET-CT, or MRI

The diagnosis is based on the complete picture—not one isolated lab value. Results should be interpreted by a hematologist or oncologist, especially when the distinction between smoldering and active multiple myeloma is unclear.

If you have concerning symptoms but are unsure what they could mean, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It cannot diagnose multiple myeloma or replace an examination, but it may help you organize symptoms and decide what to discuss with a clinician.

Speak to a doctor about persistent bone pain, unusual fatigue, repeated infections, unexplained bruising, weight loss, excessive thirst, confusion, or changes in urination. Seek urgent medical care for severe weakness, confusion, chest pain, difficulty breathing, sudden loss of urine, or symptoms that could be life-threatening or serious.